Biomaterials such as hydrogels, nanoparticles, and biodegradable polymers are being increasingly utilized to develop advanced dosage forms that aim to improve the efficiency and safety of drug delivery. Our analysis highlights a significant rise in patent filings for novel biomaterial-based technologies, reflecting innovation in smart drug delivery systems that respond to physiological stimuli and enhance targeted therapeutic effects. Concurrently, clinical trials have progressively incorporated these advanced biomaterials, demonstrating their potential in diverse therapeutic areas, including cancer treatment, diabetes management, and regenerative medicine. These trials reveal promising outcomes related to controlled release, targeted delivery, and reduced side effects. Despite these advancements, several challenges remain, including complex regulatory pathways, high production costs, and scalability issues. The review emphasizes that while the integration of biomaterials into dosage forms offers substantial improvements in therapeutic interventions, the path to widespread clinical adoption requires overcoming these barriers. Future research should focus on addressing these challenges, optimizing biomaterial properties for specific applications, and ensuring cost-effective production methods. By synthesizing data from patents and clinical trials, this review provides a comprehensive overview of the current state of biomaterial-based dosage forms and identifies key areas for future exploration and development. The chapter critically examines the evolving role of biomaterials in drug delivery systems by analyzing recent trends in patents, clinical trials, and dosage forms.